California Institute for Regenerative Medicine

California Institute for Regenerative Medicine

California Institute for Regenerative Medicine

CIRM is California's Stem Cell Agency. We fund stem cell #research to accelerate therapies for patients with unmet medical needs. Follow for news on #stemcells!
Follow us
MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient


Orchard Therapeutics Prices Initial Public Offering

Stock markets Health Costs
$200,000,000 IPO

VC-backed Orchard Therapeutics goes public

Stock markets
$150,000,000 Venture capital (Series C)
FinSMEs , Xconomy

Orchard Therapeutics Raises $150M in Series C Financing

Funding Health
$110,000,000 Venture capital (Series B)

| Gene therapy developer Orchard Therapeutics raises $110 million: Reuters

Health Funding
$16,000,000 Grant

Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS

$2,100,000 Grant
Drug Delivery Business

Brainstorm lands $2.1m Israeli grant for NurOwn stem cell therapy

$250,000,000 Post-IPO equity

Boston Business on Twitter

$20,000,000 Grant

Orchard gets $20M to trial ‘bubble boy’ gene therapy

$10,000,000 Venture capital
Cary, Morrisville, Apex, Holly Springs, Raleigh, Fuquay Varina , Triangle, Durham, Real Estate Blog

RTP's Humacyte gets $10M from California stem cell group


California Agency Awards Humacyte $9.9M for Blood Vessel Technology

Health Science Funding
The Motley Fool

Better Buy: Agenus Inc. vs. bluebird bio

The Motley Fool

Why Global Blood Therapeutics Inc. Skyrocketed and bluebird bio Inc. Sank Today

$10,000,000 Post-IPO equity

VistaGen Completes $10 Million Public Offering Therapeutics, Inc.

Health Stock markets Legal
The Motley Fool

Better Buy: bluebird bio vs. Inovio Pharmaceuticals

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

bluebird bio Inc: Catnapping in Cambridge

£21,000,000 Venture capital (Series A)

Orchard Therapeutics Launches and Announces Academic Partnerships for Development of Transformative Gene Therapies

The Motley Fool

Forget Bluebird Bio, Inc.: These 3 Stocks Are Better Buys

The Motley Fool

bluebird bio, Inc. Takes Flight Towards First Approval